SFX by Ex Libris Inc.

Title:	An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits
Source:	Science [0036-8075] Wetterau, J R yr:1998

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Chandler, Charles E. "CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans." Journal of lipid research 44.10 (2003): 1887-1901.
description	2.	Shiomi, M. "MTP inhibitor decreases plasma cholesterol levels in LDL receptor-deficient WHHL rabbits by lowering the VLDL secretion." European Journal of Pharmacology 431.1 (2001): 127-31.
description	3.	Shepherd, J. "Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety." European Heart Journal 16.1 (1995): 5-13.
description	4.	Schreiber, S. "Pharmacogenetics of inflammatory bowel disease." Baillière's best practice & research. Clinical gastroenterology 18.3 (2004): 597-609.
description	5.	Pahan, K. "Lipid-lowering drugs." Cellular and molecular life sciences 63.10 (2006): 1165-78.
description	6.	Hlavaty, T.. "Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease." Alimentary pharmacology & therapeutics 22.7 (2005): 613-626.
description	7.	Kaddis, F G G. "AMPA/kainate antagonists in the nucleus accumbens inhibit locomotor stimulatory response to cocaine and dopamine agonists." Pharmacology, biochemistry and behavior 46.3 (1993): 703-708.
description	8.	Kang, S. "Coordinate transcriptional repression of liver fatty acid-binding protein and microsomal triglyceride transfer protein blocks hepatic very low density lipoprotein secretion without hepatosteatosis." The Journal of biological chemistry 281.44 (2006): 33066-33077.
description	9.	Mascheretti, S. "The role of pharmacogenomics in the prediction of efficacy of anti-TNF therapy in patients with Crohn's disease." Pharmacogenomics 5.5 (2004): 479-486.
description	10.	Aithal, G P P. "Steering azathioprine safely: lessons from pharmacogenetics." The American journal of gastroenterology 3202-3203.
description	11.	Reijneveld, J C C. "Differential effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on the development of myopathy in young rats." Pediatric research 39.6 (1996): 1028-1035.
description	12.	Sudhop, T. "Cholesterol absorption inhibitors for the treatment of hypercholesterolaemia." Drugs 62.16 (2002): 2333-47.
description	13.	Wahli, P R R. "The PPARalpha-leukotriene B4 pathway to inflammation control." Nature 384.6604 (1996): 39-43.
description	14.	Stocco, G. "Prevalence of methylenetetrahydrofolate reductase polymorphisms in young patients with inflammatory bowel disease." Digestive diseases and sciences 51.3 (2006): 474-479.
description	15.	Shepherd, J. "Mechanism of action of fibrates." Postgraduate medical journal 69.1 (1993): 34-41.
description	16.	Burnett, John R. "MTP inhibition as a treatment for dyslipidaemias: time to deliver or empty promises?" Expert Opinion on Therapeutic Targets 11.2 (2007): 181-9.
description	17.	Grundy, S M M. "Fibric acids: effects on lipids and lipoprotein metabolism." The American journal of medicine 83.B5 (1987): 9-20.
description	18.	Armitage, J. "The safety of statins in clinical practice." Lancet, The 370.9601 (2007): 1781-90.
description	19.	Catapano A.L., Alberico L. "Mode of action of fibrates." Pharmacological research 26.4 (1992): 331-340.
description	20.	Chapman, M John J. "Beyond the statins: New therapeutic perspectives in cardiovascular disease prevention." Cardiovascular drugs and therapy 19.2 (2005): 135-139.